Discontinued Product

HexylHIBO (Cat. No. 1749) has been withdrawn from sale for commercial reasons.
Description: Group I mGlu antagonist
Alternative Names: Hexylhomoibotenic acid
Chemical Name: α-Amino-4-hexyl-2,3-dihydro-3-oxo-5-isoxazolepropanoic acid
Purity: ≥98% (HPLC)
Literature (5)

Biological Activity for HexylHIBO

HexylHIBO is a group I mGlu receptor antagonist (Ki values are 140 and 110 μM at mGlu1a and mGlu5a receptors respectively). Decreases sEPSCs in rat pyramidal neurons in vitro.

S-enantiomer also available.

Technical Data for HexylHIBO

M. Wt 256.3
Formula C12H20N2O4
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 334887-43-3
PubChem ID 3984764

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for HexylHIBO

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet is currently unavailable on-line.
Please contact Customer Service.

References for HexylHIBO

References are publications that support the biological activity of the product.

Bandrowski et al (2003) Baseline glutamate levels affect group I and II mGluRs in layer V pyramidal neurons of rat sensorimotor cortex. J.Neurophysiol. 89 1308 PMID: 12626613

Madsen et al (2001) Synthesis and pharmacology of 3-isoxazolol amino acids as selective antagonists at group I metabotropic glutamic acid receptors. J.Med.Chem. 44 1051 PMID: 11297452

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Antagonists

Keywords: HexylHIBO, HexylHIBO supplier, Group, I, mGlur, antagonists, Receptors, mGlu1, mGluR1, mGlu5, mGluR5, Glutamate, Metabotropic, Hexylhomoibotenic, acid, (Metabotropic), 1749, Tocris Bioscience

Citations for HexylHIBO

Citations are publications that use Tocris products.

Currently there are no citations for HexylHIBO.

Reviews for HexylHIBO

There are currently no reviews for this product. Be the first to review HexylHIBO and earn rewards!

Have you used HexylHIBO?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.